AEON Biopharma (AEON) Competitors

$0.78 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$0.80 +0.02 (+2.68%)

As of 05/22/2026 06:51 PM Eastern

AEON vs. JATT, ATRA, CUE, CLNN, and EXOZ

Should you buy AEON Biopharma stock or one of its competitors? MarketBeat compares AEON Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AEON Biopharma include JATT Acquisition (JATT), Atara Biotherapeutics (ATRA), Cue Biopharma (CUE), Clene (CLNN), and eXoZymes (EXOZ). These companies are all part of the "pharmaceutical products" industry.

How does AEON Biopharma compare to JATT Acquisition?

AEON Biopharma (NASDAQ:AEON) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

In the previous week, JATT Acquisition had 1 more articles in the media than AEON Biopharma. MarketBeat recorded 1 mentions for JATT Acquisition and 0 mentions for AEON Biopharma. AEON Biopharma's average media sentiment score of 0.00 equaled JATT Acquisition'saverage media sentiment score.

Company	Overall Sentiment
AEON Biopharma	Neutral
JATT Acquisition	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$5.00	N/A
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A

22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are held by institutional investors. 9.4% of AEON Biopharma shares are held by insiders. Comparatively, 20.0% of JATT Acquisition shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

AEON Biopharma's return on equity of 0.00% beat JATT Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
JATT Acquisition	N/A	-49.58%	2.84%

Summary

JATT Acquisition beats AEON Biopharma on 5 of the 9 factors compared between the two stocks.

How does AEON Biopharma compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

Atara Biotherapeutics has higher revenue and earnings than AEON Biopharma. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.73	$32.69M	-$0.67	N/A
AEON Biopharma	N/A	N/A	-$36.63M	-$5.00	N/A

70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 41.2% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 9.4% of AEON Biopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

AEON Biopharma has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. AEON Biopharma's return on equity of 0.00% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
AEON Biopharma	N/A	N/A	-994.63%

Atara Biotherapeutics currently has a consensus price target of $9.50, suggesting a potential downside of 3.06%. Given Atara Biotherapeutics' higher probable upside, equities research analysts clearly believe Atara Biotherapeutics is more favorable than AEON Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

Atara Biotherapeutics has a beta of -0.3, suggesting that its share price is 130% less volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.66, suggesting that its share price is 34% less volatile than the broader market.

In the previous week, Atara Biotherapeutics had 22 more articles in the media than AEON Biopharma. MarketBeat recorded 22 mentions for Atara Biotherapeutics and 0 mentions for AEON Biopharma. Atara Biotherapeutics' average media sentiment score of 0.15 beat AEON Biopharma's score of 0.00 indicating that Atara Biotherapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Atara Biotherapeutics	Neutral
AEON Biopharma	Neutral

Summary

Atara Biotherapeutics beats AEON Biopharma on 9 of the 15 factors compared between the two stocks.

How does AEON Biopharma compare to Cue Biopharma?

Cue Biopharma (NASDAQ:CUE) and AEON Biopharma (NASDAQ:AEON) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Cue Biopharma has a beta of 2.37, suggesting that its stock price is 137% more volatile than the broader market. Comparatively, AEON Biopharma has a beta of 0.66, suggesting that its stock price is 34% less volatile than the broader market.

Cue Biopharma has higher revenue and earnings than AEON Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	3.17	-$26.60M	-$5.58	N/A
AEON Biopharma	N/A	N/A	-$36.63M	-$5.00	N/A

35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 22.8% of AEON Biopharma shares are held by institutional investors. 1.8% of Cue Biopharma shares are held by insiders. Comparatively, 9.4% of AEON Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Cue Biopharma had 2 more articles in the media than AEON Biopharma. MarketBeat recorded 2 mentions for Cue Biopharma and 0 mentions for AEON Biopharma. AEON Biopharma's average media sentiment score of 0.00 beat Cue Biopharma's score of -0.12 indicating that AEON Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Cue Biopharma	Neutral
AEON Biopharma	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00

AEON Biopharma has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. AEON Biopharma's return on equity of 0.00% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
AEON Biopharma	N/A	N/A	-994.63%

Summary

AEON Biopharma beats Cue Biopharma on 9 of the 15 factors compared between the two stocks.

How does AEON Biopharma compare to Clene?

AEON Biopharma (NASDAQ:AEON) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

AEON Biopharma has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market. Comparatively, Clene has a beta of 0.89, indicating that its share price is 11% less volatile than the broader market.

In the previous week, Clene had 6 more articles in the media than AEON Biopharma. MarketBeat recorded 6 mentions for Clene and 0 mentions for AEON Biopharma. Clene's average media sentiment score of 0.67 beat AEON Biopharma's score of 0.00 indicating that Clene is being referred to more favorably in the news media.

Company	Overall Sentiment
AEON Biopharma	Neutral
Clene	Positive

22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 9.4% of AEON Biopharma shares are held by insiders. Comparatively, 28.3% of Clene shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

AEON Biopharma has a net margin of 0.00% compared to Clene's net margin of -25,009.70%.

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Clene	-25,009.70%	N/A	-137.98%

Clene has a consensus price target of $33.25, indicating a potential upside of 396.27%. Given Clene's higher possible upside, analysts plainly believe Clene is more favorable than AEON Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Clene has higher revenue and earnings than AEON Biopharma. Clene is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$5.00	N/A
Clene	$200K	428.13	-$26.17M	-$3.20	N/A

Summary

Clene beats AEON Biopharma on 11 of the 15 factors compared between the two stocks.

How does AEON Biopharma compare to eXoZymes?

AEON Biopharma (NASDAQ:AEON) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

AEON Biopharma has a beta of 0.66, indicating that its stock price is 34% less volatile than the broader market. Comparatively, eXoZymes has a beta of 2.85, indicating that its stock price is 185% more volatile than the broader market.

In the previous week, AEON Biopharma's average media sentiment score of 0.00 equaled eXoZymes'average media sentiment score.

Company	Overall Sentiment
AEON Biopharma	Neutral
eXoZymes	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

22.8% of AEON Biopharma shares are owned by institutional investors. 9.4% of AEON Biopharma shares are owned by company insiders. Comparatively, 72.4% of eXoZymes shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

eXoZymes has higher revenue and earnings than AEON Biopharma. eXoZymes is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$5.00	N/A
eXoZymes	$70K	1,201.74	-$9.16M	-$1.14	N/A

AEON Biopharma's return on equity of 0.00% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
eXoZymes	N/A	-220.63%	-141.26%

Summary

AEON Biopharma and eXoZymes tied by winning 6 of the 12 factors compared between the two stocks.

Get AEON Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AEON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AEON vs. The Competition

Export

Metric	AEON Biopharma	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$19.67M	$927.43M	$6.46B	$12.34B
Dividend Yield	N/A	4.84%	2.76%	5.28%
P/E Ratio	4.32	1.46	21.00	25.66
Price / Sales	N/A	119.63	562.18	86.31
Price / Cash	N/A	20.07	43.49	56.67
Price / Book	-0.19	7.59	10.41	7.14
Net Income	-$36.63M	-$3.64M	$3.57B	$335.98M
7 Day Performance	-9.21%	3.01%	6.40%	4.11%
1 Month Performance	-25.98%	76.62%	3.54%	2.52%
1 Year Performance	45.54%	126.61%	34.14%	35.04%

AEON Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AEON AEON Biopharma	0.9912 of 5 stars	$0.78 flat	N/A	+45.5%	$19.67M	N/A	4.32	5	Gap Up
JATT JATT Acquisition	N/A	$10.77 -1.6%	N/A	+994.7%	$84.04M	N/A	N/A	3	Quiet Period Expiration
ATRA Atara Biotherapeutics	1.1719 of 5 stars	$9.29 +1.5%	$9.50 +2.3%	+37.3%	$83.70M	$23.14M	N/A	330	Gap Down
CUE Cue Biopharma	0.6683 of 5 stars	$20.31 -5.0%	N/A	-96.4%	$82.26M	$27.47M	N/A	60	Gap Down
CLNN Clene	3.5728 of 5 stars	$6.43 -5.3%	$33.25 +417.0%	+182.7%	$82.19M	$200K	N/A	100	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AEON) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AEON Biopharma (AEON) Competitors

AEON vs. JATT, ATRA, CUE, CLNN, and EXOZ

How does AEON Biopharma compare to JATT Acquisition?

Summary

How does AEON Biopharma compare to Atara Biotherapeutics?

Summary

How does AEON Biopharma compare to Cue Biopharma?

Summary

How does AEON Biopharma compare to Clene?

Summary

How does AEON Biopharma compare to eXoZymes?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON vs. The Competition

AEON Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AEON Biopharma (AEON) Competitors

AEON vs. JATT, ATRA, CUE, CLNN, and EXOZ

How does AEON Biopharma compare to JATT Acquisition?

Does the media refer more to AEON or JATT?

Do analysts rate AEON or JATT?

Which has better earnings & valuation, AEON or JATT?

Do insiders & institutionals have more ownership in AEON or JATT?

Is AEON or JATT more profitable?

Summary

How does AEON Biopharma compare to Atara Biotherapeutics?

Which has better valuation and earnings, ATRA or AEON?

Do institutionals & insiders hold more shares of ATRA or AEON?

Is ATRA or AEON more profitable?

Do analysts recommend ATRA or AEON?

Which has more risk & volatility, ATRA or AEON?

Does the media refer more to ATRA or AEON?

Summary

How does AEON Biopharma compare to Cue Biopharma?

Which has more volatility & risk, CUE or AEON?

Which has higher earnings & valuation, CUE or AEON?

Do insiders & institutionals hold more shares of CUE or AEON?

Does the media prefer CUE or AEON?

Do analysts recommend CUE or AEON?

Is CUE or AEON more profitable?

Summary

How does AEON Biopharma compare to Clene?

Which has more risk and volatility, AEON or CLNN?

Does the media favor AEON or CLNN?

Do insiders and institutionals believe in AEON or CLNN?

Is AEON or CLNN more profitable?

Do analysts recommend AEON or CLNN?

Which has better earnings and valuation, AEON or CLNN?

Summary

How does AEON Biopharma compare to eXoZymes?

Which has more risk and volatility, AEON or EXOZ?

Does the media favor AEON or EXOZ?

Do analysts rate AEON or EXOZ?

Do institutionals & insiders hold more shares of AEON or EXOZ?

Which has better valuation & earnings, AEON or EXOZ?

Is AEON or EXOZ more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AEON vs. The Competition

AEON Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools